Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PBYI with free AI briefings, catalyst countdowns, and dilution alerts.

PBYI · PUMA BIOTECHNOLOGY, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$108.6M Cash on Hand
CF+ Cash Runway
Follow PBYI by email Get an email when PBYI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PBYI, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Neratinib (HKI-272)
FDA approved Jul 2017 · Nerlynx
HER2+ Metastatic Breast Cancer (MBC) Phase 3 · NCT01808573 Completed
Loperamide Early-stage Breast Cancer Phase 2 · NCT05252988 Active not recruiting
Cytotoxic Agent-LAT1 Substrate QBS10072S Glioblastoma Phase 2 · NCT02977780 Recruiting
Trastuzumab Emtansine Breast Cancer Phase 1/2 · NCT02236000 Completed
Fluorouracil GastroEsophageal Cancer Phase 2 · NCT06109467 Active not recruiting
Colestipol Early Stage HER2+ Breast Cancer Phase 2 · NCT02400476 Completed
Endocrine therapy Hormone Receptor Positive HER-2 Negative Breast Cancer Phase 2 · NCT06369285 Recruiting
DNA-PK/TOR Kinase Inhibitor CC-115 Glioblastoma Phase 2 · NCT02977780 Recruiting
Alisertib Small Cell Lung Cancer Phase 2 · NCT06095505 Recruiting
Diphenoxylate HER2-positive Breast Cancer Phase 2 · NCT03094052 Completed
Doxorubicin Breast Cancer Phase 2 · NCT01008150 Completed
Osimertinib Lung Cancer Metastatic Phase 1 · NCT04085315 Completed
Niraparib at RP2D Advanced Solid Tumor Phase 1 · NCT04502602 Active not recruiting
Neratinib Pill Gastric Cancer Phase 1 · NCT05274048 Recruiting
Neratinib at RP2D Advanced Solid Tumor Phase 1 · NCT04502602 Active not recruiting

Also used in these trials (approved or third-party drugs, not PBYI's own candidates): Lapatinib, Capecitabine, Pembrolizumab, Fulvestrant, Letrozole, Oxaliplatin, Paclitaxel, Vinorelbine, Temozolomide, Temsirolimus, Trastuzumab, Abemaciclib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PBYI holds $108.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PBYI files for a raise →

👥 Who Owns PBYI

Insiders 18.8% Institutions (214 holders) 76.5% Public and other holders 4.7%
HolderTypeShares% of sharesAs of
Alan H Auerbach
President and CEO, Director, 10% owner · +502,096 options
Insider 8,648,958 16.73% 2026-10-04
American Century Investment Management, Institution (13G, 5%+) 2,742,653 5.31% 2026-09-30
Maximo F Nougues
Chief Financial Officer · +151,608 options
Insider 230,637 0.45% 2026-07-06
Douglas M Hunt
Officer · +136,925 options
Insider 196,841 0.38% 2026-07-06
Jeffrey Jerome Ludwig
Chief Commercial Officer · +66,221 options
Insider 156,792 0.30% 2025-02-07
Brian M Stuglik
Director
Insider 113,858 0.22% 2026-06-11
Allison Dorval
Director
Insider 90,780 0.18% 2026-06-11
Michael Patrick Miller
Director
Insider 66,000 0.13% 2026-11-11
Jay M Moyes
Director
Insider 58,322 0.11% 2026-06-11
Alessandra Cesano
Director · +50,000 options
Insider 56,700 0.11% 2026-09-14
Troy Edward Wilson
Director
Insider 55,300 0.11% 2026-09-14
Adrian Senderowicz
Director
Insider 27,000 0.05% 2026-06-11

Share count 51,698,356 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PBYI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PBYI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.